Literature DB >> 20521923

The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.

Adrian Bot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20521923     DOI： 10.3109/08830185.2010.490777

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN： 0883-0185            Impact factor:   5.311


× No keyword cloud information.
  5 in total

Review 1.  Genome editing with engineered zinc finger nucleases.

Authors:  Fyodor D Urnov; Edward J Rebar; Michael C Holmes; H Steve Zhang; Philip D Gregory
Journal:  Nat Rev Genet       Date:  2010-09       Impact factor: 53.242

Review 2.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

3.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Authors:  Anniina Koski; Lotta Kangasniemi; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Iulia Diaconu; Petri Nokisalmi; Mari Raki; Maria Rajecki; Kilian Guse; Tuuli Ranki; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Leena Laasonen; Kaarina Partanen; Matteo Ugolini; Andreas Helminen; Eerika Karli; Päivi Hannuksela; Saila Pesonen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

Review 4.  NGcGM3 ganglioside: a privileged target for cancer vaccines.

Authors:  Luis E Fernandez; Mariano R Gabri; Marcelo D Guthmann; Roberto E Gomez; Silvia Gold; Leonardo Fainboim; Daniel E Gomez; Daniel F Alonso
Journal:  Clin Dev Immunol       Date:  2010-10-27

5.  Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.

Authors:  Daniel E Gomez; Ana María Vázquez; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-06-28       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.